Table 2 The characteristics of trials which included SR in the introduction or not included when there was a SR available in the literature within 12 months of trial commencement (N = 220)
Variable | SR not included but available in literature N (%) (N = 56) | SR included N (%) (N = 164) | Pearson Chi2 or Fisher’s exact test (p < 0.05) |
|---|---|---|---|
Year of publication | |||
2010 | 2 (25.0) | 6 (75.0) | 0.75 |
2011 | 3 (37.5) | 5 (62.5) | |
2012 | 4 (40.0) | 6 (60.0) | |
2013 | 2 (20.0) | 8 (80.0) | |
2014 | 4 (33.3) | 8 (66.7) | |
2015 | 5 (27.8) | 13 (72.8) | |
2016 | 8 (40.0) | 12 (60.0) | |
2017 | 5 (17.9) | 23 (82.1) | |
2018 | 5 (16.7) | 25 (83.3) | |
2019 | 7 (22.6) | 24 (77.4) | |
2020 | 11 (24.4) | 34 (75.6) | |
Journal type | |||
AJODO | 12 (28.6) | 30 (71.4) | 0.14 |
ANGLE | 12 (21.1) | 45 (78.9) | |
EJO | 17 (23.9) | 54 (76.1) | |
OCR | 4 (25.0) | 12 (75.0) | |
AOJ | 3 (100.0) | 0 (0.0) | |
JOO | 2 (28.6) | 5 (71.4) | |
JO | 6 (25.0) | 18 (75.0) | |
Continent of corresponding author | |||
Europe | 22 (20.0) | 88 (80.0) | 0.006 |
Americas | 5 (14.7) | 29 (85.3) | |
Asia or other | 29 (38.2) | 47 (61.8) | |
Ethical approval | |||
No approval or exempt from approval | 5 (35.7) | 9 (64.3) | 0.36 |
Ethical approval obtained | 51 (24.8) | 155 (75.2) | |
Involvement of statistician | |||
Not reported | 37 (24.5) | 114 (75.5) | 0.63 |
Reported | 19 (27.5) | 50 (72.5) | |
Trial registration | |||
No | 37 (28.0) | 95 (72.0) | 0.28 |
Yes | 19 (21.6) | 69 (78.4) | |
Significance of results | |||
Not significant | 28 (25.5) | 82 (74.5) | 1.00 |
Significant | 28 (25.5) | 82 (74.5) | |
Conflict of interest | |||
Conflicts exist and declared | 33 (26.4) | 92 (73.6) | 0.85 |
No conflicts to declare | 22 (24.7) | 67 (75.3) | |
Not clearly declared | 1 (16.7) | 5 (83.3) | |
Funding | |||
Industry funded and declared | 19 (20.7) | 73 (79.3) | 0.23 |
No industry sponsorship/funding to declare | 30 (31.3) | 66 (68.8) | |
Not clearly declared | 7 (22.6) | 24 (77.4) | |
Number of authors | |||
Median (IQR) | 5 (3) | 4.5 (3) | |
Impact factor | |||
Median (IQR) | 1.96 (0.41) | 1.96 (0.47) | |